Together with the effect of efipladib on p-AKT in vivo, these findings suggest that cPLA2α contributes to basal and EGF-stimulating AKT phosphorylation in CRC cells containing PI3K mutations. This evidence concerns the gene EGF and colorectal carcinoma.